BMI1 and Patent ductus arteriosus: PTC596 also reduced BMI1 levels and H2AK119ub1 in pancreatic ductal adenocarcinoma (PDA) and AML (Nishida et al., 2017; Eberle-Singh et al., 2019), but recent studies challenged the specificity of this compound.